로딩 중...
52주 최고가 대비 54.1% 위치
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $181.0M | $216.7M | $207.5M | $255.9M |
| 영업이익 | - | $-146.8M | $-177.4M | $-209.3M | $-166.9M |
| 당기순이익 | - | $-149.2M | $40.7M | $-187.1M | $-103.3M |
| 잉여현금흐름 (FCF) | - | $-127.7M | $-150.1M | $-164.7M | $12.5M |
| 수익성 비율 | |||||
| 영업이익률 | - | -81.1% | -81.9% | -100.8% | -65.2% |
| 순이익률 | - | -82.4% | 18.8% | -90.2% | -40.4% |
| ROE (자기자본이익률) | - | -33.3% | 7.4% | -44.4% | -28.4% |
| ROA (자산이익률) | - | -21.7% | 5.1% | -22.7% | -14.2% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 19.7% | -4.2% | 23.3% |
| EPS 성장률 (YoY) | - | - | 125.7% | -575.9% | 45.1% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | 49.0x | - | - |
| PBR (주가순자산배수) | - | 3.5x | 3.2x | 3.9x | 2.5x |
| PSR (주가매출배수) | - | 8.8x | 8.0x | 7.9x | 3.6x |
| FCF Yield | - | -8.1% | -8.7% | -10.0% | 1.4% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.26 | 0.23 | 0.28 | 0.30 |
| 유동비율 | - | 4.91 | 4.25 | 3.31 | 2.75 |
MOLINA HEALTHCARE INC
$179.86
$9.4B